Market barriers affect 14 percent of injectable type II diabetes mellitus prescriptions in Europe. Is your brand losing out?
Just over 10 percent of all prescriptions for injectable type II diabetes mellitus treatments in Europe are affected by barriers. Multiple brands are, therefore, losing market share. Is your brand in the mix? Find out what’s driving share gains, and what your brand can do to level the playing field in Market Access Impact (EU5): Type II Diabetes Mellitus [Injectables].
Based on a survey of 150 EU5-based diabetologists and primary care physicians from the key European markets (France, Germany, Italy, Spain, and the UK), this report covers 12 major injectable therapies in the type II diabetes market from Sanofi, Lilly, Novo Nordisk, GSK and AstraZeneca. Handy graphs and charts show at a glance which of seven different market barriers cost your brand the most market share, and which ones help you take the most share from competitors.
Not your market? Click here to see the US Edition.
Market Access Impact: Type 2 Diabetes Mellitus [Injectables] (EU5) explores key issues affecting type 2 diabetes mellitus drug manufacturers. You’ll learn:
How barriers affect market access:
How barriers affect your brand:
We surveyed 150 diabetologists and primary care physicians—30 from each EU5 country (France, Italy, Germany, Spain, UK)—chosen from the largest community of validated physicians in the world. All respondents have:
We conducted the survey between October 10-12, 2018.
At FirstWord, we stand behind our reports. If you're not completely satisfied, we’ll refund your money. Guaranteed.
FirstWord is an innovative industry intelligence leader serving over 240,000 Pharma and MedTech professionals worldwide. FirstWord offers a range of products and services designed to help your company gain a competitive edge by making key business decisions with speed and confidence.
Learn more at www.firstwordgroup.com.
All Contents Copyright © 2019 Doctor's Guide Publishing Limited All Rights Reserved